Mizuho Securities USA’s Juno Therapeutics, Inc. JUNO Stock Holding History

Mizuho Securities USA’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-24,400	Closed	-$460K	–	270
2016 Q4	$460K	Hold	24,400	–	–	0.02%	169
2016 Q3	$732K	Buy	+24,400	New	+$759K	0.06%	135
2015 Q4	–	Sell	-49,600	Closed	-$2.02M	–	176
2015 Q3	$2.02M	Buy	+49,600	New	+$2.18M	0.52%	29

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Mizuho Securities USA's JUNO Position: Q1 2017 in Review

Mizuho Securities USA sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 24,400 shares — an estimated $460K sold.

Mizuho Securities USA first reported a position in JUNO in Q3 2015 and held it in 3 quarters. The position peaked at $2.02M in Q3 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

Mizuho Securities USA reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Mizuho Securities USA sold 24,400 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $460K.
Mizuho Securities USA first reported a position in Juno Therapeutics, Inc. in Q3 2015 and held it in 3 quarters.
Mizuho Securities USA's Juno Therapeutics, Inc. position peaked at $2.02M in Q3 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Mizuho Securities USA's 13F filing for Q1 2017, filed 5 May 2017.